These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 30543826)
1. Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles. Liu M; Liang G; Zheng H; Zheng N; Ge H; Liu W Life Sci; 2019 Jan; 217():222-228. PubMed ID: 30543826 [TBL] [Abstract][Full Text] [Related]
2. Molecular basis of drug resistance in smoothened receptor: An in silico study of protein resistivity and specificity. Sinha N; Chowdhury S; Sarkar RR Proteins; 2020 Mar; 88(3):514-526. PubMed ID: 31589795 [TBL] [Abstract][Full Text] [Related]
3. Posaconazole, a Second-Generation Triazole Antifungal Drug, Inhibits the Hedgehog Signaling Pathway and Progression of Basal Cell Carcinoma. Chen B; Trang V; Lee A; Williams NS; Wilson AN; Epstein EH; Tang JY; Kim J Mol Cancer Ther; 2016 May; 15(5):866-76. PubMed ID: 26823493 [TBL] [Abstract][Full Text] [Related]
5. Development of posaconazole-based analogues as hedgehog signaling pathway inhibitors. Teske KA; Dash RC; Morel SR; Chau LQ; Wechsler-Reya RJ; Hadden MK Eur J Med Chem; 2019 Feb; 163():320-332. PubMed ID: 30529635 [TBL] [Abstract][Full Text] [Related]
6. Overcoming the emerging drug resistance of smoothened: an overview of small-molecule SMO antagonists with antiresistance activity. Zhang H; Sun Z; Liu Z; Song C Future Med Chem; 2018 Dec; 10(24):2855-2875. PubMed ID: 30557039 [TBL] [Abstract][Full Text] [Related]
7. Discovery of [1,2,4]triazolo[4,3-a]pyridines as potent Smoothened inhibitors targeting the Hedgehog pathway with improved antitumor activity in vivo. Tian N; Wu H; Zhang H; Yang D; Lv L; Yang Z; Zhang T; Quan D; Zhou L; Xie Y; Xu Y; Wei N; Zhang J; Chen M; Schmitz JC; Tian Y; Wu S Bioorg Med Chem; 2020 Aug; 28(16):115584. PubMed ID: 32690258 [TBL] [Abstract][Full Text] [Related]
8. Comment on: Triazoles bind the C-terminal domain of SMO: Illustration by docking and molecular dynamics simulations the binding between SMO and triazoles. Kozielewicz P Life Sci; 2019 May; 225():132. PubMed ID: 30965054 [No Abstract] [Full Text] [Related]
9. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Kim J; Aftab BT; Tang JY; Kim D; Lee AH; Rezaee M; Kim J; Chen B; King EM; Borodovsky A; Riggins GJ; Epstein EH; Beachy PA; Rudin CM Cancer Cell; 2013 Jan; 23(1):23-34. PubMed ID: 23291299 [TBL] [Abstract][Full Text] [Related]
10. Crystal structure of a multi-domain human smoothened receptor in complex with a super stabilizing ligand. Zhang X; Zhao F; Wu Y; Yang J; Han GW; Zhao S; Ishchenko A; Ye L; Lin X; Ding K; Dharmarajan V; Griffin PR; Gati C; Nelson G; Hunter MS; Hanson MA; Cherezov V; Stevens RC; Tan W; Tao H; Xu F Nat Commun; 2017 May; 8():15383. PubMed ID: 28513578 [TBL] [Abstract][Full Text] [Related]
11. Structural Basis of Smoothened Activation in Hedgehog Signaling. Huang P; Zheng S; Wierbowski BM; Kim Y; Nedelcu D; Aravena L; Liu J; Kruse AC; Salic A Cell; 2018 Jul; 174(2):312-324.e16. PubMed ID: 29804838 [TBL] [Abstract][Full Text] [Related]
12. MRT-92 inhibits Hedgehog signaling by blocking overlapping binding sites in the transmembrane domain of the Smoothened receptor. Hoch L; Faure H; Roudaut H; Schoenfelder A; Mann A; Girard N; Bihannic L; Ayrault O; Petricci E; Taddei M; Rognan D; Ruat M FASEB J; 2015 May; 29(5):1817-29. PubMed ID: 25636740 [TBL] [Abstract][Full Text] [Related]
13. State of the art of Smo antagonists for cancer therapy: advances in the target receptor and new ligand structures. Espinosa-Bustos C; Mella J; Soto-Delgado J; Salas CO Future Med Chem; 2019 Mar; 11(6):617-638. PubMed ID: 30912670 [TBL] [Abstract][Full Text] [Related]
14. Cholesterol Interaction Sites on the Transmembrane Domain of the Hedgehog Signal Transducer and Class F G Protein-Coupled Receptor Smoothened. Hedger G; Koldsø H; Chavent M; Siebold C; Rohatgi R; Sansom MSP Structure; 2019 Mar; 27(3):549-559.e2. PubMed ID: 30595453 [TBL] [Abstract][Full Text] [Related]
15. "Hedgehog pathway": a potential target of itraconazole in the treatment of cancer. Wei X; Liu W; Wang JQ; Tang Z J Cancer Res Clin Oncol; 2020 Feb; 146(2):297-304. PubMed ID: 31960187 [TBL] [Abstract][Full Text] [Related]
16. Molecular Modelling of Berberine Derivatives as Inhibitors of Human Smoothened Receptor and Hedgehog Signalling Pathway Using a Newly Developed Algorithm on Anti-Cancer Drugs. Kaboli PJ; Bazrafkan M; Ismail P; Ling KH Recent Pat Anticancer Drug Discov; 2017 Nov; 12(4):384-400. PubMed ID: 28969581 [TBL] [Abstract][Full Text] [Related]
17. A molecular dynamics approach to identify an oxysterol-based hedgehog pathway inhibitor. Dash RC; Maschinot CR; Hadden MK Biochim Biophys Acta Gen Subj; 2017 Feb; 1861(2):168-177. PubMed ID: 27825830 [TBL] [Abstract][Full Text] [Related]
18. Sterols in an intramolecular channel of Smoothened mediate Hedgehog signaling. Qi X; Friedberg L; De Bose-Boyd R; Long T; Li X Nat Chem Biol; 2020 Dec; 16(12):1368-1375. PubMed ID: 32929279 [TBL] [Abstract][Full Text] [Related]
19. Activation mechanism of the human Smoothened receptor. Bansal PD; Dutta S; Shukla D Biophys J; 2023 Apr; 122(7):1400-1413. PubMed ID: 36883002 [TBL] [Abstract][Full Text] [Related]
20. Structural dynamics of Smoothened (SMO) in the ciliary membrane and its interaction with membrane lipids. Kumari S; Mitra A; Bulusu G Biochim Biophys Acta Biomembr; 2022 Aug; 1864(8):183946. PubMed ID: 35483421 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]